BeiGene: Novartis Grabs Tislelizumab Rights
BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing...
China Healthcare Weekly (Jan.8)
The article analyzed the viewpoints in neurointerventional medical devices market, orthokeratology lenses market and pet medical market in China,...
BeiGene: Cancer Treatment in China--The Underestimated Opportunity
We think that cancer is underdiagnosed and undertreated in China. We analyze the data and propose two approaches for investing in this theme.
Smartkarma Originals